Prim. dr sci. med. Davorin Radosavljević
oncologist
Education:
1982. Basic studies, Faculty of Medicine, University of Belgrade
1991. Specialization in Internal Medicine, Faculty of Medicine, University of Belgrade
1996. Master’s degree in oncology, with the thesis “The importance of assessing the quality of life in the selection of a chemotherapy regimen for the treatment of patients with advanced squamous cell lung cancer“, at the Faculty of Medicine in Belgrade
2007. Title of primarius
2008. PhD with the dissertation “Prognostic model of advanced non-small cell lung cancer in patients treated with chemotherapy”
Work experience:
1985 to 2024. Employed at the Clinic for Medical Oncology
2001. Head of the Department for Chemotherapy of Solid Tumors
2011 – 2024. Director of the Clinic for Medical Oncology
2017. Adjunct Professor at the Faculty of Medicine in Belgrade
Scientific titles and participation in scientific projects:
Gained research associate title in 2009, the first re-election in January 2015, the last on January 22, 2020.
Areas of interest and scientific research are systemic chemotherapy of solid malignant lung tumors, digestive tract and urological tumors.
Participated in scientific projects of the Ministry of Science 13M13, 1996-2000. (head of NSav Dr. N. Mitrović) and 145055, 2005-2010. (head of NSav Dr. S. Jelić).
From 2011-2015. participates in two projects: Pharmacodynamics and pharmacogenomics of testing new drugs in the treatment of solid tumors, 41026, head of NSav Dr. Siniša Radulović and Role of preoperative determination of disease stage, prognostic and therapeutic markers, objectification of functional results in the decision on the strategy of rectal cancer treatment, and with the aim of improving oncological results and quality of life, 41033, head of Prof. Dr. Zoran Krivokapić.
Lectures at European meetings:
Lecturer at the 11th European Congress on Public Health in Ljubljana on November 30, 2018. Title: “The role of a Cancer Control Plan in Advancing Patient Outcomes”
Lecturer by invitation at the meeting Cost Action CA17404 “New diagnostic and therapeutic tools against multidrug resistant tumors” Belgrade, 27/28.02.2020. Title: “Targeted therapies in oncology – advantage and resistance”
Professional work in expert commissions and associations in Serbia:
For the National Guide for the Diagnosis and Treatment of Lung Cancer 2011. wrote a chapter on chemotherapy for advanced non-small cell lung cancer. For the 2012 National Guide for the Treatment and Diagnosis of Colon and Rectal Cancer. wrote a chapter on adjuvant and systemic chemotherapy for colorectal cancer.
President of the Subcommittee for Antineoplastic Medicines of the Central Committee for Medicines of the RFZO 2004-2012.
Member of the Republic Expert Commission for Oncology since 2014. and the Republican Expert Commission for Cytotoxic and Molecularly Targeted Medicines of the Ministry of Health 2015-2019. Previously, a member of the Subcommittee for Medicines of the RSK for oncology since 2008. ALIMS external expert since 2004.
Vice President of the Central Commission for Medicines of the RFZO from 2021.
Memberships in professional associations:
Member of the SLD Cancer Section since 1986. secretary of the Section 1995-2001, member of the Presidency.
Member of the Presidency of the Association of Medical Oncologists of Serbia (UMOS) since its foundation in 2005.
Member of the European Association of Medical Oncologists (ESMO) since 1996. and the American Society of Clinical Oncologists (ASCO) since 2003.
Member of the Balkan Union of Oncologists (BUON) since 1996, member of the Editorial Board of J of BUON.
Member of the Central European Cooperative Oncology Group (CECOG) since 2004
